ClinicalTrials.gg
CompletedNCT06063057Updated Jun 26, 2026

Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial

A Phase 1/2 interventional study of low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated and medium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated in Hand, Foot and Mouth Disease and Herpangina, sponsored by Sinovac Biotech Co., Ltd. Completed at 1 site in China. Open to participants aged 6 Months to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by Sinovac Biotech Co., Ltd · Phase 1/2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
744
Allocation
Randomized
Ages
6 Months to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Hand, Foot and Mouth Disease by Sinovac Biotech Co., Ltd — 4 open to participants now, 4 under way, 2 of them phase 3. Hand, Foot and Mouth Disease · Sinovac Biotech Co., Ltd.

Enrollment
8th of 15
744 · median 744
Started
2023
the only one that year
Phase 1/2
2 of 20
none open now
Registered
15th of 20
by date

Among the 20 studies in Hand, Foot and Mouth Disease by Sinovac Biotech Co., Ltd, this one is the 8th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2023, is one of 2 in phase 1/2, and was the 15th registered.

Hand, Foot and Mouth Disease

59 studies on the registry are indexed under Hand, Foot and Mouth Disease; 10 are open to participants now.

Browse Hand, Foot and Mouth Disease studies →

Open to participants now

4 of the 20 studies in Hand, Foot and Mouth Disease by Sinovac Biotech Co., Ltd are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 4 Hand, Foot and Mouth Disease studies recruiting now, 1 sets no upper age limit and 3 stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 6 Months to 59 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Hand, Foot and Mouth Disease by Sinovac Biotech Co., Ltd, or all of them as a file.
02

Study summary

The Phase I clinical trial is divided into two parts. The first part uses an open-label design, while the second part uses a randomized, double-blind, and controlled design. The goal of this clinical trial is to evaluate the tolerability and safety of a bivalent (EV71/CA16, Enterovirus 71/Coxsackievirus A16) inactivated enterovirus vaccine (Vero cell) developed by Sinovac. The vaccine will be administered to healthy adults, children aged 6 to 12 years, and children aged 6 to 71 months.

The Phase II clinical trial will also use a randomized, double-blind, and controlled design to evaluate the safety and immunogenicity of the same bivalent inactivated enterovirus vaccine (Vero cell) developed by Sinovac. This trial will involve healthy children aged 6 to 71 months.

Read the detailed description

For phase I clinical trial:

The first part of the trial plans to recruit thirty-six healthy adults aged 18-59 years and thirty-six children aged 6-12 years, with twelve participants in each of the low-dose (EV71 480 U-CA16 600 SU/0.5 ml), medium-dose (EV71 960 U-CA16 600 SU/0.5 ml), and high-dose (EV71 1920U-CA16 1200SU/0.5ml) experimental groups. The participants will receive two doses of the experimental vaccine according to a 0-1-month schedule, with adults vaccinated before children.

The second part of the trial plans to recruit seventy-two healthy children aged 6-71 months, with each dose group having twelve participants in the 6-23 months and 24-71 months age groups. The participants will receive two doses of the experimental vaccine according to a 0-1-month schedule, with each dose group being randomized, double-blind, and positive-controlled. The vaccine will be compared to a control (EV71 vaccine) at each dose level.

The dose escalation principle within each age group is from low to high doses: After completing the first dose of the lower dose stage, a safety observation period of 0-7 days will be conducted to confirm safety based on adverse event occurrence and blood routine, blood biochemistry, and urine routine tests (if any) before proceeding to the higher dose stage. The sequential enrollment principle between different age groups is from adults and children aged 6-12 years to children aged 6-71 months. After the first dose of each dose group is administered to adults, children aged 6-12 years in the same dose group can be enrolled only after a safety observation period of 0-7 days confirms safety. After completing the second dose of the medium-dose group in adults, vaccination of children aged 6-71 months can begin.

Participants in the adult and children aged 6-12 years groups will have approximately 5.5 mL of blood (2.0 mL anticoagulated blood and 3.5 mL non-anticoagulated blood) and about 2-10 mL of urine samples collected before and on day three after each dose for blood routine, blood biochemistry, and urine routine tests to evaluate vaccine safety. Only participants aged 24-71 months in the second stage of the trial will undergo these tests before the first dose. Whether participants aged 24-71 months to conduct tests on days 3 (Visit2), 30 (Visit5), and 33 (Visit6) will depend on the relevant test results in the children aged 6-12 years group. If 10% of participants in each dose stage of the children aged 6-12 years group have abnormal test results related to the vaccine that is clinically significant after the first dose, blood and urine samples will be collected from corresponding dose stage participants aged 24-71 months on days 3 (Visit2), 30 (Visit5), and 33 (Visit6).

For phase II clinical trial:

A total of six hundred children aged 6-71 months will be recruited, including 360 children aged 6-23 months and 240 children aged 24-71 months. The participants will be randomly allocated to the low-dose (EV71 480U-CA16 600SU/0.5ml), medium-dose (EV71 960U-CA16 600SU/0.5ml), high-dose (EV71 1920U-CA16 1200SU/0.5ml) experimental groups and control group (EV71 vaccine) in a 1:1:1:1 ratio.

Participants will be given two doses of either the experimental or control vaccine, administered one month apart.

During phase II of the trial, all participants will undergo blood collection on three different days: day zero, day sixty, and day 210 after vaccination. The collection will involve approximately 3.0 mL of venous blood to be separated into serum for EV71 and CA16 neutralizing antibodies assays. These assays will help evaluate the immunogenicity and immune persistence of the vaccine.

All participants in phases I/II will be observed for immediate reactions within 30 minutes after each dose, and adverse events (AEs) will be collected for the first seven days after each dose and non-solicited AEs for the first 30 days after each dose. Serious adverse events (SAEs) will be monitored from the start of vaccination until six months after completion of the vaccination course. In phase I, pregnancy events within three months (120 days) after vaccination will be collected based on self-report.

Once safety data for all participants has been obtained for 30 days after completing the vaccination course in phase I, the investigators will seek ethics approval. If the safety results are deemed satisfactory and approved by the ethics committee, the investigators will move forward to phase II clinical trial.

03

Conditions studied

  • Hand, Foot and Mouth Disease
  • Herpangina

Keywords

  • Inactivated enterovirus vaccine
  • Bivalent enterovirus vaccine
04

Who can participate

Ages eligible
6 Months to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participants aged 18-59 years, 6-12 years, and 6-71 months.
  • Participants and/or their guardians can understand and voluntarily sign the form (participants aged 8-12 years require dual signatures from both participants and their guardians).
  • Willing and able to comply with all visit schedules, sample collection, vaccine administration, and other trial procedures.
  • Provide legal identification of the participants and/or their guardians.

Exclusion criteria

Exclusion Criteria:

  • History of hand, foot, and mouth disease or EV71 vaccination.
  • Known severe allergy to the vaccine or vaccine components, such as urticaria, respiratory distress, and angioedema.
  • Congenital abnormalities or developmental disorders, genetic defects (such as Down syndrome, thalassemia, or G6PD deficiency), severe malnutrition, etc.
  • Based on medical history and physical examination, the presence of severe chronic diseases, severe cardiovascular diseases, uncontrolled hypertension or diabetes, liver or kidney diseases, etc.
  • Based on medical history and physical examination, the presence of diseases, immunodeficiency diseases, and/or blood diseases (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, thyroidectomy, autoimmune thyroid disease, any form of , asplenia, functional asplenia).
  • Based on medical history and physical examination, abnormal coagulation function (such as coagulation factor deficiency, coagulation disorders, abnormalities) or obvious bruising or bleeding disorders.
  • Based on medical history and physical examination, the presence of severe neurological diseases (epilepsy, convulsions, or seizures), mental illness, or corresponding family history.
  • Long-term use (more than 14 days) of or other agents (excluding corticosteroid sprays for allergic rhinitis and surface corticosteroid treatment for acute non-complicated dermatitis) or cytotoxic therapy or planning to receive such treatment during the trial.
  • History of long-term alcohol abuse or drug abuse.
  • Females who are breastfeeding, pregnant, or planning to become pregnant within 90 days, or females with positive pregnancy test results. Note: male participants whose spouse plans to become pregnant within 90 days are also included.
  • Received immunoglobulin and/or other blood products in the past 3 months or planning to receive such treatment during the trial.
  • Received other drugs or vaccines within the past 30 days or planning to receive such drugs or vaccines during the trial.
  • Vaccinated with attenuated within the past 14 days or subunit or inactivated vaccines within the past 7 days.
  • Suspected or confirmed fever within 72 hours before vaccination or axillary temperature >37.0℃ on the day of vaccination.
  • Clinical laboratory testing shows laboratory abnormalities beyond the reference range and with clinical significance (applicable only to Phase I clinical trials for adults/6-12-year-old children/24-71-month-old children):

A. Complete blood count: white blood cell count, , platelet count.B. Blood biochemistry: (ALT), aspartate aminotransferase (AST), total (TBIL), creatinine (CR), fasting blood glucose (Glu).C. Urine routine: urine protein (PRO).

  • Any acute illness (with or without fever) or exacerbation of chronic illness within the past 7 days.
  • According to the investigator's judgment, there are any other factors that make the participant unsuitable for participation in the clinical trial.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
744 participants (actual)

Study arms

  • Experimental
    low-dose experimental group

    phase Ⅰ: 18\~59 years old,6\~12 years old,6\~71 months old; phase Ⅱ:6\~71 months old

    Biological: low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated

  • Experimental
    medium-dose experimental group

    phase Ⅰ: 18\~59 years old,6\~12 years old,6\~71 months old; phase Ⅱ:6\~71 months old

    Biological: medium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated

  • Experimental
    high-dose experimental group

    phase Ⅰ: 18\~59 years old,6\~12 years old,6\~71 months old; phase Ⅱ:6\~71 months old

    Biological: high dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated

  • Active comparator
    Active control group

    phase Ⅰ: 6\~71 months old; phase Ⅱ:6\~71 months old

    Biological: Enterovirus type EV71 vaccine (Vero cell), Inactivated

Interventions

  • Biologicallow dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated

    Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 480 U-CA16 600 SU/0.5 ml

  • Biologicalmedium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated

    Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 960 U-CA16 600 SU/0.5 ml

  • Biologicalhigh dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated

    Bivalent Enterovirus Vaccine (Vero Cell), Inactivated antigen content: EV71 1920U-CA16 1200SU/0.5ml

  • BiologicalEnterovirus type EV71 vaccine (Vero cell), Inactivated

    Enterovirus type EV71 vaccine (Vero cell), Inactivated (Sinovac)

06

What researchers measure

Primary outcomes

  1. Phase Ⅰ: Based on adverse events, evaluate the safety of the trial vaccine among participants in different age groups

    the incidence rates of adverse reactions from the start of vaccination to 30 days after the end of the entire vaccination course

    Time frame: 30 days

  2. Phase Ⅱ: Evaluate the immunogenicity of the trial vaccine in the target population.

    The seroconversion rate of EV71 and CA16 neutralizing antibodies in children aged 6-71 months 30 days after the end of the entire vaccination course.

    Time frame: 30 days

Secondary outcomes

  1. Phase Ⅰ: Based on adverse events, evaluate the safety of the trial vaccine among participants in different age groups.

    \- The incidence rate of adverse reactions from 0-7 days after each dose.

    Time frame: 7 days

  2. Phase Ⅰ: Based on adverse events, evaluate the safety of the trial vaccine among participants in different age groups.

    \- The incidence rate of serious adverse events from the start of vaccination to 6 months after the end of the entire vaccination course.

    Time frame: 6 months

  3. Phase Ⅰ: Based on laboratory abnormalities, evaluate the safety of the trial vaccine among participants in different age groups.

    -The incidence rate of clinically significant abnormal blood biochemistry, blood routine, and urine routine indexes within 3 days after each dose.

    Time frame: 3 days

  4. Phase Ⅱ: Evaluate other immunogenicity indicators of the trial vaccine.

    -The seropositive rates of EV71 and CA16 neutralizing antibodies 30 days after the end of the entire vaccination course.

    Time frame: 30 days

  5. Phase Ⅱ: Evaluate other immunogenicity indicators of the trial vaccine.

    -The GMTs (Geometric Mean Titers) of EV71 and CA16 neutralizing antibodies 30 days after the end of the entire vaccination course.

    Time frame: 30 days

  6. Phase Ⅱ: Evaluate other immunogenicity indicators of the trial vaccine.

    -The GMFRs (Geometric Mean Fold Rise) of EV71 and CA16 neutralizing antibodies 30 days after the end of the entire vaccination course.

    Time frame: 30 days

  7. Phase Ⅱ: Based on adverse events, evaluate the safety of the trial vaccine.

    -The incidence rate of adverse reactions from the start of vaccination to 30 days after the end of the entire vaccination course.

    Time frame: 30 days

  8. Phase Ⅱ: Based on adverse events, evaluate the safety of the trial vaccine.

    -The incidence rate of adverse reactions from 0-7 days after each dose.

    Time frame: 7 days

  9. Phase Ⅱ: Based on adverse events, evaluate the safety of the trial vaccine.

    -The incidence rate of SAEs from the start of vaccination to 6 months after the end of the entire vaccination course.

    Time frame: 6 months

  10. Phase Ⅱ: Evaluate the immune persistence of the trial vaccine.

    -The seropositive rates of neutralizing antibodies against EV71 and CA16 6 months after the vaccination course.

    Time frame: 6 months

  11. Phase Ⅱ: Evaluate the immune persistence of the trial vaccine.

    -The seropositive rates of EV71, and CA16 neutralizing antibodies 6 months after the end of the entire vaccination course.

    Time frame: 6 months

  12. Phase Ⅱ: Evaluate the immune persistence of the trial vaccine.

    -The GMTs of EV71, and CA16 neutralizing antibodies 6 months after the end of the entire vaccination course.

    Time frame: 6 months

07

Study locations

1 site
  • Dayao County Center for Disease Control and Prevention
    Chuxiong, Yunnan, China
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in Dec 2025, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2023
First posted
Oct 2, 2023
StartActual
Sep 20, 2023
Primary completionActual
Dec 19, 2025
CompletionActual
Mar 10, 2026
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06063057
Responsible party
Sponsor
First posted
Oct 2, 2023
Start date
Sep 20, 2023
Primary completion
Dec 19, 2025
Completion
Mar 10, 2026
Last update
Jun 26, 2026

Study contacts

Zheng Yan
principal investigator · Yunnan Provincial Center for Disease Control and Prevention

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion